LENZ Therapeutics is progressing rapidly with its LNZ100 for presbyopia, aiming for a 2025 U.S. launch in a market valued at ...

Monovision is the name given to the art and science of fitting contact lenses on a patient who has developed presbyopia. Presbyopia is the unavoidable change in vision that usually occurs at ...

The FDA has approved the first and so far only pharmacological treatment for presbyopia, a sight condition that typically starts in middle age and involves difficulty in focusing on near objects ...

Presbyopia is caused by a stiffening in the lens of the eye that develops in people after the age of 40, and affects an estimated 128 million people in the US. AbbVie is recommending Vuity ...

ATHENS, Greece — In this Healio Video Perspective from the ESCRS winter meeting, Ramza Diamanti, MD, discusses the importance of patient communication when using presbyopia-correcting lenses.

To assess visual performance and overall satisfaction with EDOF CLs, Kamiya and colleagues conducted a prospective study in 42 eyes of 21 subjects with presbyopia. They assessed visual acuity at ...

As we age, many changes occur within our bodies, including a gradual decline in our reading vision, known as presbyopia. This natural process, which typically begins in our 40s, can lead to ...

LENZ Therapeutics, Inc.'s LNZ100 eye drops show strong phase 3 results for presbyopia, outperforming competitors. Click here ...

Alcon Inc. ALC recently introduced the Clareon PanOptix Pro intraocular lens (IOL) for cataract patients in the United States. PanOptix Pro leverages proprietary ENLIGHTEN NXT Optical technology to ...

New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Upon FDA approval, commercial launch activities to commence immediately with ...